113 related articles for article (PubMed ID: 19435362)
1. Targeting of epidermal growth factor receptor (EGFR)-expressing tumor cells with sterically stabilized affibody liposomes (SAL).
Beuttler J; Rothdiener M; Müller D; Frejd FY; Kontermann RE
Bioconjug Chem; 2009 Jun; 20(6):1201-8. PubMed ID: 19435362
[TBL] [Abstract][Full Text] [Related]
2. Improved therapeutic activity of HER2 Affibody-targeted cisplatin liposomes in HER2-expressing breast tumor models.
Alavizadeh SH; Akhtari J; Badiee A; Golmohammadzadeh S; Jaafari MR
Expert Opin Drug Deliv; 2016; 13(3):325-36. PubMed ID: 26578208
[TBL] [Abstract][Full Text] [Related]
3. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.
Kirpotin D; Park JW; Hong K; Zalipsky S; Li WL; Carter P; Benz CC; Papahadjopoulos D
Biochemistry; 1997 Jan; 36(1):66-75. PubMed ID: 8993319
[TBL] [Abstract][Full Text] [Related]
4. Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule.
Friedman M; Orlova A; Johansson E; Eriksson TL; Höidén-Guthenberg I; Tolmachev V; Nilsson FY; Ståhl S
J Mol Biol; 2008 Mar; 376(5):1388-402. PubMed ID: 18207161
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of four affibody-based near-infrared fluorescent probes for optical imaging of epidermal growth factor receptor positive tumors.
Qi S; Miao Z; Liu H; Xu Y; Feng Y; Cheng Z
Bioconjug Chem; 2012 Jun; 23(6):1149-56. PubMed ID: 22621238
[TBL] [Abstract][Full Text] [Related]
6. HER2-specific affibody-conjugated thermosensitive liposomes (Affisomes) for improved delivery of anticancer agents.
Puri A; Kramer-Marek G; Campbell-Massa R; Yavlovich A; Tele SC; Lee SB; Clogston JD; Patri AK; Blumenthal R; Capala J
J Liposome Res; 2008; 18(4):293-307. PubMed ID: 18937120
[TBL] [Abstract][Full Text] [Related]
7. Engineering and characterization of a bispecific HER2 x EGFR-binding affibody molecule.
Friedman M; Lindström S; Ekerljung L; Andersson-Svahn H; Carlsson J; Brismar H; Gedda L; Frejd FY; Ståhl S
Biotechnol Appl Biochem; 2009 Aug; 54(2):121-31. PubMed ID: 19492986
[TBL] [Abstract][Full Text] [Related]
8. PEGylated liposomes modified with LHRH analogs for tumor targeting.
He Y; Zhang L; Song C
J Control Release; 2011 Nov; 152 Suppl 1():e29-31. PubMed ID: 22195906
[No Abstract] [Full Text] [Related]
9. Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells.
Zhou Y; Drummond DC; Zou H; Hayes ME; Adams GP; Kirpotin DB; Marks JD
J Mol Biol; 2007 Aug; 371(4):934-47. PubMed ID: 17602702
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin-alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells.
Wang Y; Zhou J; Qiu L; Wang X; Chen L; Liu T; Di W
Biomaterials; 2014 May; 35(14):4297-309. PubMed ID: 24565522
[TBL] [Abstract][Full Text] [Related]
11. Promoted Delivery of Salinomycin to Lung Cancer Through Epidermal Growth Factor Receptor Aptamers Coupled DSPE-PEG2000 Nanomicelles.
Leng D; Hu J; Huang X; He W; Wang Y; Liu M
J Nanosci Nanotechnol; 2018 Aug; 18(8):5242-5251. PubMed ID: 29458573
[TBL] [Abstract][Full Text] [Related]
12. The use of PEGylated liposomes to prolong the circulation lifetime of salvianolic acid B.
Zhang L; Han L; Sun X; Gao D; Qin J; Wang J
Fitoterapia; 2012 Jun; 83(4):678-89. PubMed ID: 22391022
[TBL] [Abstract][Full Text] [Related]
13. Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modified with PEGylated liposomes.
He Y; Zhang L; Song C
Int J Nanomedicine; 2010 Sep; 5():697-705. PubMed ID: 20957221
[TBL] [Abstract][Full Text] [Related]
14. iRGD-conjugated DSPE-PEG2000 nanomicelles for targeted delivery of salinomycin for treatment of both liver cancer cells and cancer stem cells.
Mao X; Liu J; Gong Z; Zhang H; Lu Y; Zou H; Yu Y; Chen Y; Sun Z; Li W; Li B; Gao J; Zhong Y
Nanomedicine (Lond); 2015; 10(17):2677-95. PubMed ID: 26355733
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer.
Zalba S; Contreras AM; Haeri A; Ten Hagen TL; Navarro I; Koning G; Garrido MJ
J Control Release; 2015 Jul; 210():26-38. PubMed ID: 25998052
[TBL] [Abstract][Full Text] [Related]
16. Preparation and in vitro targeting of sterically stabilized liposomes modified with chimeric TNT-3 monoclonal antibody.
Pan H; Niu GQ; Pan J; Lu WY
Yao Xue Xue Bao; 2006 Jun; 41(6):506-12. PubMed ID: 16927823
[TBL] [Abstract][Full Text] [Related]
17. Optimization of tumor-selective targeting by basic fibroblast growth factor-binding peptide grafted PEGylated liposomes.
Terada T; Mizobata M; Kawakami S; Yamashita F; Hashida M
J Control Release; 2007 Jun; 119(3):262-70. PubMed ID: 17467100
[TBL] [Abstract][Full Text] [Related]
18. A synthetic peptide mediated active targeting of cisplatin liposomes to Tie2 expressing cells.
Mai J; Song S; Rui M; Liu D; Ding Q; Peng J; Xu Y
J Control Release; 2009 Nov; 139(3):174-81. PubMed ID: 19576253
[TBL] [Abstract][Full Text] [Related]
19. Effect of surface modified liposomes on the aggregation of platelets and tumor cells.
Keil C; Zeisig R; Fichtner I
Thromb Haemost; 2005 Aug; 94(2):404-11. PubMed ID: 16113832
[TBL] [Abstract][Full Text] [Related]
20. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity.
Guo XF; Zhu XF; Shang Y; Zhang SH; Zhen YS
Clin Cancer Res; 2010 Apr; 16(7):2085-94. PubMed ID: 20332319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
